Edition:
United Kingdom

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.78USD
12 Dec 2017
Change (% chg)

$-0.05 (-2.73%)
Prev Close
$1.83
Open
$1.85
Day's High
$1.85
Day's Low
$1.77
Volume
10,448
Avg. Vol
58,008
52-wk High
$3.69
52-wk Low
$1.66

Chart for

About

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $30.56
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-‍Stonepine Capital Management reports 6.6 pct passive stake in Vical

* ‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​ Source text: (http://bit.ly/2z2Y7Nh) Further company coverage:

15 Nov 2017

BRIEF-Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock

* Vical Incorporated announces pricing of $25 million underwritten public offering of common stock

08 Nov 2017

BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION

* VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION

24 Oct 2017

BRIEF-Vical reports Q3 loss per share $0.27

* Vical reports third quarter 2017 financial and operational results

23 Oct 2017

BRIEF-Vical Inc files for common stock offering of up to $23.0 mln

* Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​ Source: (http://bit.ly/2gnoSUA) Further company coverage:

16 Oct 2017

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

10 Oct 2017

BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA

* Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial

02 Oct 2017

BRIEF-Vical Inc Q2 loss per share $0.30

* Vical reports second quarter 2017 financial and operational results

08 Aug 2017

Competitors

Earnings vs. Estimates